πŸ‡ΊπŸ‡Έ FDA
Patent

US 8828936

Therapeutic use of SCGB3A2

granted A61KA61K38/1709A61K38/18

Quick answer

US patent 8828936 (Therapeutic use of SCGB3A2) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/1709, A61K38/18, A61P, A61P11/00